Overview

Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and effectiveness of TAK-583, once daily (QD), in the treatment of neuropathy caused by diabetes mellitus.
Phase:
Phase 2
Details
Lead Sponsor:
Takeda